Emergence of clinical applications of endothelin system inhibitors.
Goto
Katsutoshi
K
Department of Pharmacology, Institute of Basic Medical Sciences,University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan. kgoto@ md.tsukuba.ac.jp
Miyauchi
Takashi
T
Yanagisawa
Masashi
M
D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016282:Aspartic Acid Endopeptidases / Q000378:metabolism; D002317:Cardiovascular Agents / Q000494:pharmacology*; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D000072396:Endothelin-Converting Enzymes; D016232:Endothelins / Q000378:metabolism*; D006801:Humans; D008666:Metalloendopeptidases / Q000378:metabolism; D044022:Receptor, Endothelin A / Q000378:metabolism; D044023:Receptor, Endothelin B / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
D000700:Analgesics; D000970:Antineoplastic Agents; D002317:Cardiovascular Agents; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D016232:Endothelins; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes